Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Asset disposition
Class action filed
|
|
Cellectar Biosciences, Inc. (CLRB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/14/2023 |
8-K
| Quarterly results |
| 06/29/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/04/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi... |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1study of Iopofosine I 131 in Pediatric Brain Tumors FLORHAM PARK, N.J., September 22, 2022 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing Phase 1study of iopofosine I 131 in children and adolescents with inoperable relapsed or refractory high grade gliomas . The grant was awarded by the National Institute of Health’ s National Cancer Institute based upon the initial signals of efficacy in the Phase 1study, which is an international, open-label, dose escalation, safety study. The funding allows for an expansion ..." |
|
| 09/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/05/2022 |
8-K
| Quarterly results |
| 07/21/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/21/2022 |
8-K
| Quarterly results|
Docs:
|
"Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update FLORHAM PARK, N.J., March 21, 2022 -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2021 and provided a corporate update. Fourth Quarter and Recent Corporate Highlights · Presented data from 11 multiple myeloma patients from the company’ s ongoing Phase 2 CLOVER-1study of iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition. The patients included in this report were triple class refractory had a median 7.2 prior lines of therapy, 50% classified as high risk, showed a mean over..." |
|
| 03/15/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 02/25/2022 |
8-K
| Quarterly results |
| 12/14/2021 |
8-K
| Quarterly results |
| 11/16/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Cellectar’ s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors FLORHAM PARK, N.J., November 16, 2021 -- Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in a Phase 1study of iopofosine I-131 in children and adolescents with relapsed and refractory high grade gliomas and soft tissue sarcomas, exhibited positive changes in various tumor parameters. The Phase 1study is an international, open-label, dose escalation, safety study of iopofosine in children and adolescents with relapsed or refractory cancers, specifically HGGs, high risk neuroblastoma and select soft tissue sarcomas. ..." |
|
| 11/08/2021 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 10/25/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/22/2021 |
8-K
| Quarterly results |
| 09/15/2021 |
8-K
| Quarterly results |
| 08/18/2021 |
8-K
| Quarterly results |
| 08/16/2021 |
8-K
| Quarterly results |
| 08/09/2021 |
8-K
| Quarterly results |
| 07/13/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/12/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
|
|
|